IBDEI1MJ ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,27549,1,4,0)
 ;;=4^N07.2
 ;;^UTILITY(U,$J,358.3,27549,2)
 ;;=^5015561
 ;;^UTILITY(U,$J,358.3,27550,0)
 ;;=N07.3^^106^1363^25
 ;;^UTILITY(U,$J,358.3,27550,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27550,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,27550,1,4,0)
 ;;=4^N07.3
 ;;^UTILITY(U,$J,358.3,27550,2)
 ;;=^5015562
 ;;^UTILITY(U,$J,358.3,27551,0)
 ;;=N07.3^^106^1363^26
 ;;^UTILITY(U,$J,358.3,27551,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27551,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,27551,1,4,0)
 ;;=4^N07.3
 ;;^UTILITY(U,$J,358.3,27551,2)
 ;;=^5015562
 ;;^UTILITY(U,$J,358.3,27552,0)
 ;;=N07.4^^106^1363^23
 ;;^UTILITY(U,$J,358.3,27552,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27552,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ diffus endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,27552,1,4,0)
 ;;=4^N07.4
 ;;^UTILITY(U,$J,358.3,27552,2)
 ;;=^5015563
 ;;^UTILITY(U,$J,358.3,27553,0)
 ;;=N07.5^^106^1363^27
 ;;^UTILITY(U,$J,358.3,27553,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27553,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,27553,1,4,0)
 ;;=4^N07.5
 ;;^UTILITY(U,$J,358.3,27553,2)
 ;;=^5015564
 ;;^UTILITY(U,$J,358.3,27554,0)
 ;;=N07.6^^106^1363^22
 ;;^UTILITY(U,$J,358.3,27554,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27554,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,27554,1,4,0)
 ;;=4^N07.6
 ;;^UTILITY(U,$J,358.3,27554,2)
 ;;=^5015565
 ;;^UTILITY(U,$J,358.3,27555,0)
 ;;=N07.7^^106^1363^28
 ;;^UTILITY(U,$J,358.3,27555,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27555,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,27555,1,4,0)
 ;;=4^N07.7
 ;;^UTILITY(U,$J,358.3,27555,2)
 ;;=^5015566
 ;;^UTILITY(U,$J,358.3,27556,0)
 ;;=N07.8^^106^1363^31
 ;;^UTILITY(U,$J,358.3,27556,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27556,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ oth morphologic lesions
 ;;^UTILITY(U,$J,358.3,27556,1,4,0)
 ;;=4^N07.8
 ;;^UTILITY(U,$J,358.3,27556,2)
 ;;=^5015567
 ;;^UTILITY(U,$J,358.3,27557,0)
 ;;=N07.9^^106^1363^32
 ;;^UTILITY(U,$J,358.3,27557,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27557,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ unsp morphologic lesions
 ;;^UTILITY(U,$J,358.3,27557,1,4,0)
 ;;=4^N07.9
 ;;^UTILITY(U,$J,358.3,27557,2)
 ;;=^5015568
 ;;^UTILITY(U,$J,358.3,27558,0)
 ;;=N08.^^106^1363^21
 ;;^UTILITY(U,$J,358.3,27558,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27558,1,3,0)
 ;;=3^Glomerular disorders in diseases classified elsewhere
 ;;^UTILITY(U,$J,358.3,27558,1,4,0)
 ;;=4^N08.
 ;;^UTILITY(U,$J,358.3,27558,2)
 ;;=^5015569
 ;;^UTILITY(U,$J,358.3,27559,0)
 ;;=C90.00^^106^1364^9
 ;;^UTILITY(U,$J,358.3,27559,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27559,1,3,0)
 ;;=3^Multiple myeloma not having achieved remission
 ;;^UTILITY(U,$J,358.3,27559,1,4,0)
 ;;=4^C90.00
 ;;^UTILITY(U,$J,358.3,27559,2)
 ;;=^5001752
 ;;^UTILITY(U,$J,358.3,27560,0)
 ;;=C90.01^^106^1364^8
 ;;^UTILITY(U,$J,358.3,27560,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27560,1,3,0)
 ;;=3^Multiple myeloma in remission
 ;;^UTILITY(U,$J,358.3,27560,1,4,0)
 ;;=4^C90.01
 ;;^UTILITY(U,$J,358.3,27560,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,27561,0)
 ;;=C90.02^^106^1364^7
 ;;^UTILITY(U,$J,358.3,27561,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27561,1,3,0)
 ;;=3^Multiple myeloma in relapse
 ;;^UTILITY(U,$J,358.3,27561,1,4,0)
 ;;=4^C90.02
